Alkermes plc. Income (Loss) from Continuing Operations, Per Diluted Share
Alkermes plc. (ALKS) reported Income (Loss) from Continuing Operations, Per Diluted Share of $1.43 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2026-02-25
- Alkermes plc. income (loss) from continuing operations, per diluted share for the quarter ending 2025-09-30 was $0.49, a 12.50% decline year-over-year.
- Alkermes plc. income (loss) from continuing operations, per diluted share for the quarter ending 2025-06-30 was $0.52, a 5.45% decline year-over-year.
- Alkermes plc. income (loss) from continuing operations, per diluted share for the quarter ending 2025-03-31 was $0.13, a 43.48% decline year-over-year.
- Alkermes plc. income (loss) from continuing operations, per diluted share for the quarter ending 2024-09-30 was $0.56, a 5.66% increase year-over-year.
- Alkermes plc. income (loss) from continuing operations, per diluted share for fiscal 2025 was $1.43, a 35.00% decline from fiscal 2024.
- Alkermes plc. income (loss) from continuing operations, per diluted share for fiscal 2024 was $2.20, a 28.10% decline from fiscal 2023.
- Alkermes plc. income (loss) from continuing operations, per diluted share for fiscal 2023 was $3.06.
- Alkermes plc. income (loss) from continuing operations, per diluted share for fiscal 2022 was -$0.20, a 143.48% decline from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.43 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $0.49 10-Q · filed 2025-10-28 | $1.14 10-Q · filed 2025-10-28 | ||
| 2025-06-30 | $0.52 10-Q · filed 2025-07-29 | $0.65 10-Q · filed 2025-07-29 | ||
| 2025-03-31 | $0.13 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | $2.20 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $0.56 10-Q · filed 2025-10-28 | $1.33 10-Q · filed 2025-10-28 | ||
| 2024-06-30 | $0.55 10-Q · filed 2025-07-29 | $0.78 10-Q · filed 2025-07-29 | ||
| 2024-03-31 | $0.23 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $3.06 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $0.53 10-Q · filed 2024-10-24 | $2.10 10-Q · filed 2024-10-24 | ||
| 2023-06-30 | $1.63 10-Q · filed 2024-07-24 | $1.56 10-Q · filed 2024-07-24 | ||
| 2023-03-31 | -$0.07 10-Q · filed 2024-05-01 | |||
| 2022-12-31 | -$0.20 10-K · filed 2025-02-12 | |||
| 2021-12-31 | $0.46 10-K · filed 2024-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |